anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Side effects following the use of vinblastine sulfate are dose related. Therefore, following administration of more than the recommended dose, patients can be expected to experience these effects in an exaggerated fashion. (See CLINICAL PHARMACOLOGY, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS.) There is no specific antidote. In addition, neurotoxicity similar to that with vincristine sulfate may be observed. Since the major route of excretion may be through the biliary system, toxicity from this drug may be increased when there is hepatic insufficiency.
Renal transplant participants who will be subjected to a combined immunosuppressive treatment containing mycophenolate mofetil, will be followed-up until the end of the study (after 12 months), or until the participant's death, withdrawal, or lost contact with the participant, whichever occurs first. The choice of treatment will be made prior to enrolment by the treating physician. The treatment will be administered according to applicable therapeutic protocol and Summary of Product Characteristics (SmPC).
INTRODUCTION: Severe ischemia is a rare complication of radial artery catheterization (RAC). This study aims to summarize risk factors of RAC-elicited severe hand ischemia, preventive, and therapeutic management.
METHODS: Literature search was conducted in eight electronic English and Chinese databases to identify relevant published cases. Data of interest was extracted and analyzed.
RESULTS: Database search identified 28 articles reporting cases of 57 patients developing hand ischemia following RAC. Patients aged between 1 day and 88 years. The indications for RAC included surgery, shock, cardiac arrest, and Neonatal Intensive Care Unit (NICU) admission. Identified risk factors included pre-existing vascular diseases, hypotension, arterial anatomical abnormality or small diameter, vasoconstrictors, and catheter-related problems. Totally, 18 patients complained pain; 32 developed discoloration; 19 pulselessness; 3 paresthesia; 13 swolleness and 19 coldness. Eventually, 30 patients recovered well, but 20 patients unfortunately underwent digital amputation and three patients deceased due to non-RAC-related causes.
CONCLUSION: Severe hand ischemia following RAC is a rare complication, with the reported incidence of approximately 0.09%. There is no definite predictor for RAC-related hand ischemia, but patients with risk factors are prone to the occurrence of hand ischemia. It's vital to initiate early recognition and proactive strategies for a best practice RAC insertion.
BACKGROUND: Periodontal diseases are associated with dysbiosis in the oral microbial communities. Managing oral biofilms is therefore key for preventing these diseases. Management protocols often include over-the-counter antimicrobial mouth rinses, which lack data on their effects on the oral microbiome's ecology, bacterial composition, metabolic activity, and dysbiosis resilience. This study examined the efficacy of antimicrobial mouth rinses to halt dysbiosis in in vitro oral biofilms under periodontitis-simulating conditions.
METHODS: Multispecies oral biofilms were grown on hydroxyapatite discs (HADs) and rinsed daily with one of six mouth rinses. Positive and negative controls were included. After three rinses, biofilms were analyzed with viability quantitative polymerase chain reaction and visualized using scanning electron microscopy. Supernatants of rinsed biofilms were used for metabolic activity analysis. In addition, human oral keratinocytes were exposed to rinsed biofilms to assess their inflammatory response. All outputs were analyzed for correlation using Spearman coefficient.
RESULTS: Product-related changes were observed in the rinsed biofilms. Three of the six tested mouth rinses could significantly prevent dysbiosis with ≥30% reduction in pathobiont abundance relative to the control. These biofilms had lower metabolic activity, and the exposed human oral keratinocyte produced less interleukin-8. Interleukin-8 production correlated to both pathobiont quantity and the metabolic activity of the biofilms.
CONCLUSION: Some mouth rinses could support biofilm resilience and stop dysbiosis evolution in the biofilm model, with a clear product-related effect. Such mouth rinses can be considered for patients under maintenance/supportive periodontal therapy to prevent/delay disease recurrence. Others are more useful for different periodontal therapy stages.
A medical adhesive composition comprising, based upon the total weight of the composition, from about 50wt.% to about 99.9wt.% of one or more α-cyanoacrylate monomers and from about 0.1wt.% to about 5wt.% of one or more non-steroidal anti-inflammatory drugs (NSAIDs). Preferred NSAIDs include ibuprofen, ketoprofen, topiramate, curcumin and acetaminophen. The preferred α-cyanoacrylate monomers include 3-(2-cyano-acryloyloxy)-hexanoic acid ethyl ester (Et-β-CPL-CA) and 2-octylcyanoacrylate (2-OCA). The composition may further comprise an antimicrobial agent such as Triclosan. The compositions provide enhanced fibroblast proliferation and reduced cytotoxicity compared to compositions that do not contain NSAID. In another aspect, a kit comprising a first container that contains the medical adhesive composition and a second container that contains a polymerization initiator or accelerator.
Digital storytelling group will discuss the ethical analyses of the cases with ethical issues written by themselves outside the classroom environment. Each small group of 6-7 people will present their ethical case analyses to other group members in the classroom through digital storytelling.
Colorectal cancer (CRC) is significantly contributed to global cancer mortality rates. Treating CRC is particularly challenging due to metastasis and drug resistance. There is a pressing need for new treatment strategies against metastatic CRC. Photodynamic therapy (PDT) offers a well-established, minimally invasive treatment option for cancer with limited side effects. Hypericin (HYP), a potent photosensitizer for PDT, has been documented to induce cytotoxicity and apoptosis in various types of cancers. However, there are few reports on the inhibitory effects of HYP-mediated PDT on the metastatic ability of CRC cells. Here, we evaluate the inhibitory effects of HYP-mediated PDT against metastatic CRC cells and define its underlying mechanisms. Wound-healing and Transwell assays show that HYP-mediated PDT suppresses migration and invasion of CRC cells. F-actin visualization assays indicate HYP-mediated PDT decreases F-actin formation in CRC cells. TEM assays reveal HYP-mediated PDT disrupts pseudopodia formation of CRC cells. Mechanistically, immunofluorescence and western blotting results show that HYP-mediated PDT upregulates E-cadherin and downregulates N-cadherin and Vimentin. HYP-mediated PDT also suppresses key EMT regulators, including Snail, MMP9, ZEB1 and α-SMA. Additionally, the expressions of RhoA and ROCK1 are downregulated by HYP-mediated PDT. Together, these findings suggest that HYP-mediated PDT inhibits the migration and invasion of HCT116 and SW620 cells by modulating EMT and RhoA-ROCK1 signaling pathway. Thus, HYP-mediated PDT presents a potential therapeutic option for CRC.
PURPOSE:To provide an agent for promoting bone metabolism, containing vitamin D or its derivative and a water-soluble zinc compound as active components, having synergistic effect to promote the metabolism of bones and effective to decrease the dose of vitamin D and reduce its side effects. CONSTITUTION:The objective agent for promoting bone metabolism can be produced by compounding vitamin D or its derivative [preferably vitamin D3, 1alpha, 25(OH)2D3] and a water-soluble zinc compound (e.g. zinc salt of hydrogen halide, sulfuric acid, citric acid, etc.) as active components. The zinc salt exhibits synergistic effect to the bone metabolism promotion of vitamin D or its derivative, decreases the dose of vitamin D or its derivative and reduces the side effects of vitamin D, etc. The dose of vitamin D or its derivative is about >=5ng/kg daily and that of the water-soluble zinc compound is >=0.05mg/kg daily in terms of metallic zinc.
Subjects (approximately 500) will be initially enrolled from a general screening population in the first phase, and during the second phase from the colposcopy clinic population (approximately 300) based on their referral abnormal Pap cytology conducted within 120-days in order to achieve a statistically viable number of normal women, women with Cervical Intra-epithelial Neoplasia (CIN1/2) and women with CIN3+, as described in Section 6.1, "Cervical Cytology Enrollment Targets". After the Cervical Neoplasia Detection System (CNDS) test, a sample for Hybrid Capture 2 Human papillomavirus (HPV) testing and liquid cytology will be collected in addition to colposcopy and biopsy, if indicated.

A key component of effective screening studies designed to evaluate new detection modalities is verification of the gold standard comparison by which estimates of sensitivity and specificity are generated. In the case of screening studies in general and studies of cervical disease detection in particular, the avoidance of verification bias is a priority. For the purposes of the proposed study, CIN3 or cancer (CIN3+) must be verified or adjudicated by multiple histopathologists. Results for women with CIN1 or CIN2 will be confirmed histopathologically and analyzed as a separate subgroup because these lesions often regress to normal in certain populations and tend to cause disagreement among histopathologists. In order to verify absence of disease (i.e., CIN1 or less severe), the investigators will not rely on histopathology, as it would not be ethical to perform multiple biopsies or excisional procedures to obtain a tissue sample for histopathology. Instead, women will be considered normal if they have negative referral cytology, are free of high risk HPV and are colposcopically normal.
A collection of monoclonal antibodies whose members are directed against human leukocyte interferons (HLI) which are natural or obtained by recombinant DNA technique is described. The monoclonal antibodies are preferably secreted by various hybridomas. It has emerged that some of these monoclonal antibodies are mutually inhibitory, i.e. bind together to HLI while others are not mutually inhibitory, i.e. do not bind simultaneously to HLI. It has furthermore emerged that the collection consists of groups of monoclonal antibodies whose members recognise different epitopes (antigenic determinants) of HLI. Accordingly, one member from each of these groups of antibodies can be employed for a solid-phase sandwich assay for HLI. Furthermore, one antibody from the collection can be used for purification of HLI by affinity chromatography.
FIELD: bioengineering.SUBSTANCE: options of immune body or its epitope-linking fragment, that are specific in terms of beta amyloid peptide 1-40 are suggested. Each option is characterized in that contains areas VH and VL, or 6 CDR out of light and heavy chains. Described: coding nucleic acid; options of repository lines of cells (hybrid) with collection numbers DSM ACC2844, DSM ACC2845, DSM ACC2846, and line of cells including said polynucleotide, to receive immune bodies. Suggested: therapeutic composition to treat diseases or distresses due to or linked with amyloid or amyloid-like proteins, and set to determine amyloid protein in the biologic sample, - using immune body. Options of method of immune body production are described: with use of hybrid and coding nucleic acid. Described: method of diagnostic of aptitude for disease or state linked with amyloidosis; method of determination of degree of content of amyloidogenic plaque in the tissue; method of monitoring of minimum residual disease linked with amyloid; method of forecast of individual sensibility; method of treatment or alleviation of the diseases linked with amyloidosis; method of decreasing of number of plaque and their load in brain; mewthod of decreasing of total number of soluble protein of amyloid, and method of keeping or increasing of cognitive memory volume of the individual - using immune body or its epitope-linking fragment. Options of use of immune body or its epitope-linking fragment for medicament production are described.EFFECT: new immune bodies that can be used in therapy and diagnostic of Alzheimer's disease and other listed amyloidosises.54 cl, 20 dwg, 13 tbl, 3 ex
The present invention relates to a Chinese medicinal tea bag for treating acute and chronic pharyngitis and a production method. The Chinese medicinal tea bag is prepared from the following raw materials by the weight part ratio: 340 to 360 shares of folium isatidis, 340 to 360 shares of honeysuckle flower, 340 to 360 shares of tangerine pith, 200 to 220 shares of boat-fruited sterculia seed, 340 to 360 shares of ophiopogon root, 340 to 360 shares of common lophatherum herb and 200 to 220 shares of green tea. According to experiments of pharmacodynamics, the medicine of the present invention proves that the medicine can treat acute pharyngitis and chronic pharyngitis with the symptoms of dry throats, sore pharynx, burn, dysphagia, foreign body sensation, thirst, fever, the intolerance of cold, etc. According to the recognition of motherland medicine on pharyngitis and a theory prescription of the traditional Chinese medicine, the medicine of the present invention proves to have obvious treating action and preventing action on the acute pharyngitis and the chronic pharyngitis by clinical tests and the research on pharmacologia and pharmacodynamics. The Chinese medicinal tea bag of the present invention is convenient to be administered by patients; the effects are visible, and the excellence rate is as high as 53.3%. The medicine of the present invention has particularly obvious effects on treating the dry throats and the follicular hyperplasia at the rear walls of the throats without toxic or side effects.
The present invention relates to a gel patch used for treating dyspepsia and a preparing method thereof. The Chinese medicine gel patch which is disclosed in the invention for treating pain is composed of 2%-100% of Chinese medicine extract and 98%-0% of medicinal supplementary material. The whitethorn and rice sprout are water-soluble extract extracted with a water extraction method. The radish seeds are liposoluble component extracted with a Soxhlet extraction method. The cassia seed is the liposoluble component extracted with an alcohol extraction method. The Chinese medicine patch disclosed by the invention is prepared through mixing molecular gel and hydrogel. The liposoluble medicine enters the skin through liposoluble channel. The water-soluble medicine enters the skin through water-soluble channel. Thus the problem of separation of medicine and substrate is prevented. Simultaneously the lipophilic substrate has a certain repulsion force to water-soluble medicine as well as the water-soluble substrate to lipophilic medicine. The absorption of medicine is impelled and the medicine effect is increased.
The quality of sleep is directly linked to the quality of human life. Irradiation of blood in the transcutaneous vascular technique is believed to decrease blood viscosity and platelet aggregation; activates superoxide dismutase; promotes increased oxygen content and stimulates microcirculation, it also stimulates increased serotonin production and cortisol reduction. Serotonin functions include sleep initiation, mood improvement, anxiety and depression. Therefore, the objective of the present project is to evaluate the effect of ILIB on salivary biomarkers related to stress and sleep. Therefore, participants with problems related to sleep quality will be selected and divided into 2 groups, group 1 undergoing ILIB Therapy twice a week for 30 minutes and group 2 the same frequency and time of application, but with placebo equipment. At the end of 10 sessions, salivary biomarkers related to stress and sleep and the patients' perception will be evaluated through specific questionnaires on the effect of ILIB on sleep, stress and relaxation.
In women with hormone sensitive early breast cancer, taking a hormone therapy (also known as endocrine therapy) for at least five years after surgery is very effective at reducing the risk of the cancer returning. However, for some women their cancer may eventually become resistant to these drugs. POETIC-A Registration part will identify those who have a higher risk of developing resistance to standard endocrine therapy (ET). At least 8000 women diagnosed with early stage breast cancer will enter the Registration stage from 80 centres. Study doctors will use aromatase inhibitors (AIs), a type of ET, to treat the cancer for between 2 weeks and 6 months before surgery. A sample will be taken from the cancer during surgery and the study laboratory will measure a biological marker called Ki67. If the level of Ki67 does not drop after 2 weeks of AI treatment, the patient is likely to be less sensitive to endocrine therapy, and the study doctor will explore additional treatments after surgery in the POETIC-A Treatment part. Everyone who agrees to join the Treatment stage (2032 patients) will be randomly put into one of the 2 treatment groups; Group1: ET only; or Group2: ET plus a new drug called abemaciclib. The first aim of the Treatment stage is to confirm whether abemaciclib given in combination with ET is more effective than giving ET alone in preventing the cancer coming back. The study laboratory will perform a second test on the cancer sample, called an AIR-CIS test. This test aims to find out if particular groups of patients based on their tumour biology are more suitable for treatment with abemaciclib. Patients in Group 2 will receive ET plus abemaciclib for 2 years. Patients in both groups will have regular study visits during this period.
Participants assigned to the waitlist control condition only complete questionnaires during the study period. After they have completed their 6-week study activities, they will receive access to the FACT intervention.
Patients with relapsed or refractory (R/R) mature natural killer cell and T-cell lymphoma have limited treatment options. To evaluate pralatrexate's performance and factors influencing its safety and efficacy in R/R peripheral T-cell lymphoma (PTCL), we performed a pooled analysis of data from 4 similarly designed, regulatory-mandated prospective clinical trials. Of 221 patients (median age, 59 years; 67.0% male) in the study population, 48.9% had PTCL not otherwise specified (PTCL-NOS), 21.3% angioimmunoblastic T-cell lymphoma, and 11.8% ALK-negative anaplastic large cell lymphoma (ALCL). Patients received pralatrexate for a median of 2.56 months (range, 0.03-24.18) and had a 40.7% objective response rate with a median duration of response of 9.1 months, progression-free survival 4.6 months, and overall survival 16.3 months. The most common treatment-related all-grade adverse events were stomatitis, thrombocytopenia, white blood cell count decrease, pyrexia, and vomiting. Subgroup exploratory analyses suggest improved efficacy with 1 prior line of chemotherapy vs 2 or ≥4 prior lines; PTCL-NOS or ALCL vs transformed mycosis fungoides; chemotherapy and transplant before pralatrexate vs chemotherapy alone or chemotherapy with other nontransplant treatments. In conclusion, these pooled analysis results further support using pralatrexate in patients with R/R PTCL. Prospective studies are needed to confirm the findings of subgroups analyses.
Many patients with fatigue do not visit a physician. In patients who do consult the general practitioner, the cause of their fatigue is explained in about a quarter: 8 percent has a somatic cause while psychosocial causes explain 16 percent. In about three quarters the cause of fatigue remains unexplained. Because of the low prevalence of somatic causes the general practitioner will be reluctant to perform additional examinations but a thorough physical examination is essential. In patients with a longer duration of fatigue (> 6 months) it is indicated to expand inquiries. This starts with extending history taking in the direction of consanguinity and hereditary diseases. More comprehensive blood tests and investigation of sleep are important further steps. Referral to a specialist is essential as specialists are more familiar with scripts of rare diseases. The prognosis of longer lasting fatigue is bad, especially in the case of fatigue meeting criteria for ME/CFS. Treatment of longer lasting fatigue could compromise of psycho-education, exercise and specific therapies for sleeping disorders.
Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient treated with DUEXIS has any signs or symptoms of anemia, monitor hemoglobin or hematocrit.

NSAIDs, including DUEXIS, may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase the risk. Monitor these patients for signs of bleeding [see Drug Interactions (7)].
A nasal spray composition and method of use for the treatment of a variety of viral infections, including the common told. The effective ingredient in the treatment is the compound L-Lysine monohydrochloride (lysine). The crystalline lysine is ground into a fine powder and dispersed in an aqueous medium. The solution is dispensed using an atomizer that delivers a fine mist. When used at specified time intervals throughout each 24 hour period, the duration of cold symptoms or symptoms of other common viral infections is noticeably diminished. There are no side effects and no toxic levels of lysine. The nasal spray composition is quite stable and non-irritating.
Participants will be provided with a calorie-matched refined grain-based side dish every day for 4 weeks for incorporation into their self-selected diet. The refined grain-based side dishes will be prepared at the Penn State Metabolic Kitchen and ingredients high in saturated fat, refined sugar or sodium will not be used. These will be sides commonly eaten in the U.S. (e.g. pasta made with white flour and white rice, white bread rolls). During this treatment, participants will be told not to consume potatoes.
PURPOSE: Provided are skin care compositions containing an N-substituted fatty acid amide and retinol or retinyl ester. CONSTITUTION: Provided is a skin conditioning composition containing: (a) from about 0.001% to about 10% of retinol or a retinyl ester; (b) from about 0.0001 % to about 50% of a N-substituted fatty acid amide of formula 1 which inhibits at least 20% of LRAT or ARAT catalyzed retinol esterification at 100 microM concentration as measured by an in vitro Microsomal Assay; and (c) a cosmetically acceptable vehicle. Wherein R1 is alkyl or alkoxy having from 1 to 10 carbon atoms; R2 =alkyl or alkenyl having from 8 to 25 carbon atoms; R3 =alkyl containing 1 to 5 carbon atoms, or a phosphate ester. The composition prevents and treats dry skin, photodamaged skin, appearance of wrinkles, age spots, aged skin, increases stratum corneum flexibility, lightening skin color, controls sebum excretion and generally increases the quality of skin. The composition may be used to improve skin desquamation and epidermal differentiation. The N-substituted fatty acid amide substantially improves the performance of retinol or a retinyl ester.